178 related articles for article (PubMed ID: 28962026)
1. Pharmacodynamics of teicoplanin against MRSA.
Ramos-Martín V; Johnson A; McEntee L; Farrington N; Padmore K; Cojutti P; Pea F; Neely MN; Hope WW
J Antimicrob Chemother; 2017 Dec; 72(12):3382-3389. PubMed ID: 28962026
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic/pharmacodynamic evaluation of teicoplanin against Staphylococcus aureus in a murine thigh infection model.
Watanabe E; Matsumoto K; Ikawa K; Yokoyama Y; Shigemi A; Enoki Y; Umezaki Y; Nakamura K; Ueno K; Terazono H; Morikawa N; Takeda Y
J Glob Antimicrob Resist; 2021 Mar; 24():83-87. PubMed ID: 33290889
[TBL] [Abstract][Full Text] [Related]
3. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.
Bowker KE; Noel AR; MacGowan AP
J Antimicrob Chemother; 2009 Nov; 64(5):1044-51. PubMed ID: 19759041
[TBL] [Abstract][Full Text] [Related]
4. Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection.
Ogawa R; Kobayashi S; Sasaki Y; Makimura M; Echizen H
Int J Clin Pharmacol Ther; 2013 May; 51(5):357-66. PubMed ID: 23458228
[TBL] [Abstract][Full Text] [Related]
5. Optimization of dosing regimens of vancomycin, teicoplanin, linezolid and daptomycin against methicillin-resistant
Wei X; Zhao M; Xiao X
J Chemother; 2021 Dec; 33(8):547-553. PubMed ID: 34080519
[TBL] [Abstract][Full Text] [Related]
6. In Vivo Pharmacodynamic Target Investigation of Two Bacterial Topoisomerase Inhibitors, ACT-387042 and ACT-292706, in the Neutropenic Murine Thigh Model against Streptococcus pneumoniae and Staphylococcus aureus.
Lepak AJ; Seiler P; Surivet JP; Ritz D; Kohl C; Andes DR
Antimicrob Agents Chemother; 2016 Jun; 60(6):3626-32. PubMed ID: 27044547
[TBL] [Abstract][Full Text] [Related]
7. In vivo pharmacodynamic activity of the glycopeptide dalbavancin.
Andes D; Craig WA
Antimicrob Agents Chemother; 2007 May; 51(5):1633-42. PubMed ID: 17307987
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of teicoplanin in children.
Ramos-Martín V; Paulus S; Siner S; Scott E; Padmore K; Newland P; Drew RJ; Felton TW; Docobo-Pérez F; Pizer B; Pea F; Peak M; Turner MA; Beresford MW; Hope WW
Antimicrob Agents Chemother; 2014 Nov; 58(11):6920-7. PubMed ID: 25224001
[TBL] [Abstract][Full Text] [Related]
9. Application of pharmacokinetic/pharmacodynamic modelling and simulation for the prediction of target attainment of ceftobiprole against meticillin-resistant Staphylococcus aureus using minimum inhibitory concentration and time-kill curve based approaches.
Barbour AM; Schmidt S; Zhuang L; Rand K; Derendorf H
Int J Antimicrob Agents; 2014 Jan; 43(1):60-7. PubMed ID: 24183800
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetic/Pharmacodynamic Target Attainment of Vancomycin, at Three Reported Infusion Modes, for Methicillin-Resistant
Song X; Han M
Front Cell Infect Microbiol; 2022; 12():874401. PubMed ID: 35873144
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamics of telavancin studied in an in vitro pharmacokinetic model of infection.
MacGowan AP; Noel AR; Tomaselli S; Elliott HC; Bowker KE
Antimicrob Agents Chemother; 2011 Feb; 55(2):867-73. PubMed ID: 21078943
[TBL] [Abstract][Full Text] [Related]
12. Pharmacodynamic comparison of linezolid, teicoplanin and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil.
Kuti JL; Kiffer CR; Mendes CM; Nicolau DP
Clin Microbiol Infect; 2008 Feb; 14(2):116-23. PubMed ID: 18076672
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic/Pharmacodynamic Evaluation of a Novel Aminomethylcycline Antibiotic, KBP-7072, in the Neutropenic Murine Pneumonia Model against Staphylococcus aureus and Streptococcus pneumoniae.
Lepak AJ; Zhao M; Liu Q; Wang P; Wang Y; Bader JC; Ambrose PG; Andes DR
Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30559140
[TBL] [Abstract][Full Text] [Related]
14. Use of Monte Carlo simulation to evaluate the development of vancomycin resistance in meticillin-resistant Staphylococcus aureus.
Mei Q; Ye Y; Zhu YL; Cheng J; Yang HF; Liu YY; Li HR; Li JB
Int J Antimicrob Agents; 2015 Jun; 45(6):652-6. PubMed ID: 25813394
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection.
Knudsen JD; Fuursted K; Raber S; Espersen F; Frimodt-Moller N
Antimicrob Agents Chemother; 2000 May; 44(5):1247-54. PubMed ID: 10770759
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacokinetics and pharmacodynamics of the lantibiotic NAI-107 in a neutropenic murine thigh infection model.
Lepak AJ; Marchillo K; Craig WA; Andes DR
Antimicrob Agents Chemother; 2015 Feb; 59(2):1258-64. PubMed ID: 25512404
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
Chen CY; Xie M; Gong J; Yu N; Wei R; Lei LL; Zhao SM; Li RM; Dong X; Zhang XL; Zhou Y; Li SL; Cui YM
Front Pharmacol; 2023; 14():1132367. PubMed ID: 37188268
[No Abstract] [Full Text] [Related]
18. Ceftaroline efficacy against high-MIC clinical Staphylococcus aureus isolates in an in vitro hollow-fibre infection model.
Singh R; Almutairi M; Alm RA; Lahiri SD; San Martin M; Chen A; Ambler JE
J Antimicrob Chemother; 2017 Oct; 72(10):2796-2803. PubMed ID: 29091195
[TBL] [Abstract][Full Text] [Related]
19. In vivo pharmacodynamic activity of tomopenem (formerly CS-023) against Pseudomonas aeruginosa and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.
Sugihara K; Sugihara C; Matsushita Y; Yamamura N; Uemori M; Tokumitsu A; Inoue H; Kakuta M; Namba E; Nasu H; Koga T
Antimicrob Agents Chemother; 2010 Dec; 54(12):5298-302. PubMed ID: 20921311
[TBL] [Abstract][Full Text] [Related]
20. PK/PD modeling of daptomycin against MRSA and MRSE and Monte Carlo simulation for bacteremia treatment.
Menezes B; Alves I; Staudt K; Beltrame B; Michelin L; de Araújo BV; Tasso L
Braz J Microbiol; 2021 Dec; 52(4):1967-1979. PubMed ID: 34337679
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
